tdamess
Very helpful member
- Joined
- Jul 29, 2009
- Messages
- 1,297
- Reason
- Loved one DX
- Diagnosis
- 07/2009
- Country
- US
- State
- ma.
- City
- halifax
hi , all just had a friend tell me about this any one know anything or have thoughts
Serdaxin(R)
Serdaxin is presently in clinical development for Major Depressive Disorder, and may work as a dual enhancer of serotonin and dopamine in the brain through a novel mechanism of action. In Rexahn's Phase IIa, proof of concept study, Serdaxin showed numerical differences versus placebo for response and remission rates, as well as significance in the severe patient population versus placebo. The trial also demonstrated Serdaxin to be safe and well tolerated without the appearance of serious side effects that are commonly linked to currently marketed antidepressants. Rexahn is moving forward with a larger phase II clinical trial, involving approximately 300 subjects using an independent central rater to reduce bias associated with depression trials. Preliminary results are expected in Q4 2011. Additionally, Serdaxin has shown neuroprotective potential in animals treated with neurotoxins, and may have important applications in the treatment of human neurodegenerative disorders such as Parkinson's disease (PD) and Alzheimer disease (AD). Moreover, animal model studies also suggest that Serdaxin reduces aggressive behavior and relieves anxiety.
this is the line that caught my attention
neuroprotective potential in animals treated with neurotoxins, and may have important applications in the
Serdaxin(R)
Serdaxin is presently in clinical development for Major Depressive Disorder, and may work as a dual enhancer of serotonin and dopamine in the brain through a novel mechanism of action. In Rexahn's Phase IIa, proof of concept study, Serdaxin showed numerical differences versus placebo for response and remission rates, as well as significance in the severe patient population versus placebo. The trial also demonstrated Serdaxin to be safe and well tolerated without the appearance of serious side effects that are commonly linked to currently marketed antidepressants. Rexahn is moving forward with a larger phase II clinical trial, involving approximately 300 subjects using an independent central rater to reduce bias associated with depression trials. Preliminary results are expected in Q4 2011. Additionally, Serdaxin has shown neuroprotective potential in animals treated with neurotoxins, and may have important applications in the treatment of human neurodegenerative disorders such as Parkinson's disease (PD) and Alzheimer disease (AD). Moreover, animal model studies also suggest that Serdaxin reduces aggressive behavior and relieves anxiety.
this is the line that caught my attention
neuroprotective potential in animals treated with neurotoxins, and may have important applications in the